Valuation Newron Pharmaceuticals S.p.A. Deutsche Boerse AG
Stocks
NP5
IT0004147952
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
23:49:18 30/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 8.450 EUR | +3.05% |
|
-24.33% | -65.93% |
Company Valuation: Newron Pharmaceuticals S.p.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 27.93 | 27.99 | 94.91 | 185.1 | 511.9 | 180.7 | - | - |
| Change | - | 0.21% | 239.07% | 94.99% | 176.62% | -64.7% | - | - |
| Enterprise Value (EV) 1 | 27.93 | 60.23 | 114.7 | 225.7 | 521.2 | 194.9 | 198.8 | 180.7 |
| Change | - | 115.64% | 90.45% | 96.77% | 130.92% | -62.6% | 2.01% | -9.12% |
| P/E | -1.86x | -1.6x | -5.84x | 11.2x | -38.9x | -6.59x | 246x | 2.98x |
| PBR | - | -2x | -3.17x | 130x | -46x | - | - | - |
| PEG | - | -0.1x | 0.82x | -0x | 0x | -0.1x | -2x | 0x |
| Capitalization / Revenue | 4.85x | 4.59x | 10.5x | 3.6x | 26.8x | 21.3x | 4.53x | 1.51x |
| EV / Revenue | 4.85x | 9.88x | 12.7x | 4.39x | 27.3x | 23x | 4.99x | 1.51x |
| EV / EBITDA | -2.3x | -4.6x | -10x | 8.56x | -115x | -6.81x | 7.32x | 1.92x |
| EV / EBIT | -2.26x | -4.53x | -9.86x | 8.62x | -111x | -86.4x | 202x | 1.92x |
| EV / FCF | - | -5.42x | -11.3x | -12.8x | 16.1x | 2.63x | 3.26x | 1.74x |
| FCF Yield | - | -18.4% | -8.85% | -7.81% | 6.2% | 38% | 30.7% | 57.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.84 | -0.98 | -0.91 | 0.85 | -0.66 | -1.305 | 0.035 | 2.89 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5.762 | 6.094 | 9.057 | 51.39 | 19.13 | 8.488 | 39.86 | 120 |
| EBITDA 1 | -12.15 | -13.1 | -11.43 | 26.36 | -4.525 | -28.63 | 27.16 | 94 |
| EBIT 1 | -12.36 | -13.3 | -11.63 | 26.17 | -4.697 | -2.255 | 0.9847 | 94 |
| Net income 1 | -14.9 | -17.49 | -16.22 | 15.84 | -13.24 | -29.99 | -1.956 | 58 |
| Net Debt 1 | - | 32.24 | 19.8 | 40.64 | 9.287 | 14.21 | 18.13 | - |
| Reference price 2 | 1.565 | 1.568 | 5.318 | 9.510 | 25.645 | 8.603 | 8.603 | 8.603 |
| Nbr of stocks (in thousands) | 17,845 | 17,845 | 17,845 | 19,459 | 19,961 | 21,239 | - | - |
| Announcement Date | 15/03/22 | 14/03/23 | 19/03/24 | 31/03/25 | 23/03/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.87x | 7.45x | 14.96x | 1.42% | 71.53B | |
| 31.24x | 9x | 28.05x | 0.04% | 60.12B | |
| 34.13x | 6.11x | 18.31x | 0.95% | 48.85B | |
| 34.64x | 3.34x | 14.41x | -.--% | 44.28B | |
| -21.08x | 228.26x | -22.72x | -.--% | 43.83B | |
| 47.85x | 5.53x | 30.37x | -.--% | 41.53B | |
| 27.07x | 7.8x | 20.09x | 0.42% | 30.13B | |
| 32.39x | 6.91x | 17.94x | -.--% | 27.98B | |
| -70.94x | 13.62x | -69.42x | -.--% | 25.25B | |
| Average | 15.13x | 32.00x | 5.78x | 0.32% | 43.72B | |
| Weighted average by Cap. | 19.23x | 31.83x | 9.93x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- NWRN Stock
- NP5 Stock
- Valuation Newron Pharmaceuticals S.p.A.
Select your edition
All financial news and data tailored to specific country editions
